2025 was a pivotal year for cardiovascular medicine, marked by significant advancements and paradigm shifts in treatment and risk assessment. The field witnessed a series of groundbreaking discoveries and updates that are reshaping clinical practice. Here's a closer look at some of the most notable developments of the year.
Aspirin's Declining Role: One of the most controversial topics in cardiology in 2025 was the role of aspirin in cardiovascular health. Long-held assumptions about aspirin's benefits were challenged by new research, prompting a reevaluation of its routine use. Studies revealed that the risks associated with lifelong aspirin use substantially outweigh the potential benefits. This led to a shift in prescribing practices, with researchers suggesting that superior antiplatelet therapies like clopidogrel may replace aspirin as the preferred choice. In fact, one clinical trial had to be halted early due to excess deaths, further underscoring the need for a reevaluation of aspirin's role.
Single Pill Combinations (SPCs) and Fixed Dose Combinations (FDCs): There was a significant push for SPCs and FDCs as first-line hypertension treatment in 2025. This urgency was driven by the need for changes to the Pharmaceutical Benefits Scheme (PBS) to make these combinations more accessible. However, despite the calls for action, the PBS restrictions have not been lifted, and updates to the Australian Hypertension Guidelines have not been released as of the article's publication.
CRISPR Gene Editing Breakthrough: Australian researchers made a significant leap in CRISPR gene editing technology in 2025. The first in-human trial successfully used gene editing to manage cholesterol, leading to significant reductions in both cholesterol and triglycerides. This breakthrough therapy is the first to simultaneously address both issues and has been hailed as a potential breakthrough for managing mixed lipid disorders.
New Dyslipidaemia Management Guidelines: The European Society of Cardiology and the European Atherosclerosis Society released new international recommendations for dyslipidaemia management in 2025. These guidelines proposed a more aggressive approach to lipid-lowering regimens, moving away from the long-used low and slow tactic. The recommendations also emphasized the importance of utilizing Lp(a) for heart disease prevention, a long-overlooked cardiovascular risk factor that could prevent a significant number of heart attacks, strokes, and early deaths.
PCSK9 Inhibitors in Cholesterol Management: The annual American Heart Association scientific sessions featured multiple studies on PCSK9 inhibitors in cholesterol management. One of the studies found that pairing PCSK9 inhibitors with statins provided additional protection, cutting the risk of cardiovascular death, heart attack, or ischemic stroke by more than a quarter. This breakthrough has the potential to significantly improve cholesterol management and cardiovascular health.
In conclusion, 2025 was a transformative year for cardiovascular medicine, with advancements in treatment, risk assessment, and gene editing. However, it also highlighted the need for ongoing research and adaptation in clinical practice. As cardiologists from Italy, Germany, and the US noted, interventional cardiology in 2025 has been characterized by pivotal clinical trials that have reshaped daily practice and clarified long-term expectations for percutaneous therapies. These developments are paving the way for a brighter and healthier future in cardiovascular medicine.
